CN105749292A - Composition for promoting insulin absorption and preparation method of composition - Google Patents
Composition for promoting insulin absorption and preparation method of composition Download PDFInfo
- Publication number
- CN105749292A CN105749292A CN201610111649.XA CN201610111649A CN105749292A CN 105749292 A CN105749292 A CN 105749292A CN 201610111649 A CN201610111649 A CN 201610111649A CN 105749292 A CN105749292 A CN 105749292A
- Authority
- CN
- China
- Prior art keywords
- parts
- insulin
- composition
- hydrogenated
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 102000004877 Insulin Human genes 0.000 title claims abstract description 42
- 108090001061 Insulin Proteins 0.000 title claims abstract description 42
- 229940125396 insulin Drugs 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000010521 absorption reaction Methods 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000001737 promoting effect Effects 0.000 title abstract description 9
- 239000004359 castor oil Substances 0.000 claims abstract description 16
- 235000019438 castor oil Nutrition 0.000 claims abstract description 16
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 16
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 16
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 claims abstract description 16
- UGTZMIPZNRIWHX-UHFFFAOYSA-K sodium trimetaphosphate Chemical compound [Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)O1 UGTZMIPZNRIWHX-UHFFFAOYSA-K 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 28
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 14
- 150000001412 amines Chemical class 0.000 claims description 14
- 235000019270 ammonium chloride Nutrition 0.000 claims description 14
- CNXJITYCNQNTBD-UHFFFAOYSA-L dipotassium;hexadecyl phosphate Chemical compound [K+].[K+].CCCCCCCCCCCCCCCCOP([O-])([O-])=O CNXJITYCNQNTBD-UHFFFAOYSA-L 0.000 claims description 14
- 210000002969 egg yolk Anatomy 0.000 claims description 14
- 229940067606 lecithin Drugs 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 239000000787 lecithin Substances 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000010792 warming Methods 0.000 claims description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 8
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 abstract 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical class CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 abstract 2
- NDLNTMNRNCENRZ-UHFFFAOYSA-N 2-[2-hydroxyethyl(octadecyl)amino]ethanol Chemical compound CCCCCCCCCCCCCCCCCCN(CCO)CCO NDLNTMNRNCENRZ-UHFFFAOYSA-N 0.000 abstract 2
- KXHFAYYFSKKIID-UHFFFAOYSA-N CCCCCCCCCCCCCCCC[K] Chemical compound CCCCCCCCCCCCCCCC[K] KXHFAYYFSKKIID-UHFFFAOYSA-N 0.000 abstract 2
- 229910019142 PO4 Inorganic materials 0.000 abstract 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 abstract 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
- 239000010452 phosphate Substances 0.000 abstract 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 2
- 229960001285 quercetin Drugs 0.000 abstract 2
- 235000005875 quercetin Nutrition 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 229940126701 oral medication Drugs 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000003538 oral antidiabetic agent Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a composition for promoting insulin absorption and a preparation method of the composition. The composition comprises the following raw materials in parts by weight: 10-30 parts of dodecyl dimethyl amine oxide, 20-40 parts of hydrogenated castor oil, 40-60 parts of cetyl potassium quercetin phosphate, 10-20 parts of didecyl chain quaternary ammonium salt, 2-8 parts of octadecyl diethanolamine, 3-10 parts of disodium hydrogen phosphate, 20-50 parts of sodium trimetaphosphate and 10-40 parts of hydrogenated egg yolk lecithin. The preparation method comprises the following steps: mixing dodecyl dimethyl amine oxide, hydrogenated castor oil, cetyl potassium quercetin phosphate and didecyl chain quaternary ammonium salt, heating to 50-60 DEG C, adding disodium hydrogen phosphate, sodium trimetaphosphate and hydrogenated egg yolk lecithin, heating to 80-85 DEG C, stirring to react for 20-30 minutes, adding octadecyl diethanolamine, and uniformly mixing, thereby obtaining the composition. By adopting the composition disclosed by the invention, the blood sugar reduction effect of insulin can be improved.
Description
Technical field
The present invention relates to biomedicine field, particularly relate to a kind of composition and method of making the same promoting absorption of insulin.
Background technology
Insulin is applicable to type 1 diabetes patient, and owing to self islet beta cell function is impaired, insulin secretion is definitely not enough, is accomplished by insulin treatment when morbidity, and needs lifelong insulin replacement therapy to sustain life and to live.Account for diabetes total number of persons 5%.Type 2 diabetes mellitus patient, on the basis of life style and Combined with Oral Antidiabetic Agents, if blood glucose is still not up to controlling target, can start the therapeutic alliance of oral drugs and insulin.When generally after the multiple oral drugs therapeutic alliance of larger dose, HbA1c is still greater than 7.0%, it is possible to consider to start insulin treatment.Neopathy also differentiates the diabetics of becoming thin of difficulty with type 1 diabetes.Diabetic duration (includes the type 2 diabetes mellitus patient of new diagnosis), when the weight loss without obvious inducement occurs, it should use of exogenous insulin as early as possible.For the Newly diagnosed diabetes patient that blood glucose is higher, owing to oral drugs are difficult to make blood glucose obtain satisfied control, and alleviating rapidly of hyperglycemia toxicity can partly alleviate insulin resistant and reverse β cell function, thus the type 2 diabetes mellitus of new diagnosis with obvious hyperglycemia time can use insulin intensive treatment.Also have some in particular cases also must apply insulin treatment: peri-operation period；Insulin need to be used to tide over a critical period when serious acute complications or stress state occur, such as diabetic ketoacidosis, Hyperosmolar hyperglycemic state, lactic acidosis, infection etc. temporarily；Severe chronic complication occurs, such as diabetic foot, severe diabetes nephropathy etc.；Merge some serious diseases, such as coronary heart disease, cerebrovascular, hematopathy, hepatopathy etc.；The women of gestational diabetes and pregnancy in women with diabetes mellitus, trimester of pregnancy, childbirth before and after, age of sucking, as blood glucose can not alone diet control reach requirement desired value time, need to treat with insulin, disable oral antidiabetic drug.
But the insulin of prior art can not well be utilized absorption due to its Drug resistance.
Summary of the invention
The present invention is directed to the deficiencies in the prior art, it is provided that a kind of composition and method of making the same promoting absorption of insulin, said composition can be effectively promoted the absorption of insulin.
The present invention is by the following technical solutions:
Promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 10～30 parts, castor oil hydrogenated 20～40 parts, 40～60 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 10～20 parts, octadecyldiethanol amine 2～8 parts, disodium hydrogen phosphate 3～10 parts, sodium trimetaphosphate 20～50 parts, hydrogenated yolk lecithin 10～40 parts.
As to further improvement of the present invention, promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 20 parts, castor oil hydrogenated 30 parts, 50 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 15 parts, octadecyldiethanol amine 5 parts, disodium hydrogen phosphate 6 parts, sodium trimetaphosphate 30 parts, hydrogenated yolk lecithin 30 parts.
The preparation method promoting the compositions of absorption of insulin, comprises the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 50 DEG C～60 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 80～85 DEG C, stirring reaction 20～30min；
(3) add octadecyldiethanol amine, stir,.
As to further improvement of the present invention, the heating-up temperature of step (1) is 55 DEG C.
As to further improvement of the present invention, step (2) is warming up to 85 DEG C of reaction 25min.
Beneficial effect
The compositions of the present invention can promote the absorption of insulin, makes insulin faster play a role, and improves the blood sugar decreasing effect of insulin.
Detailed description of the invention
Below in conjunction with specific embodiment, the present invention is further described in detail.
The several specific embodiments being only the application of following discloses, but the application is not limited to this, the changes that any person skilled in the art can think of, all should drop in the protection domain of the application.
Embodiment 1
Promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 10 parts, castor oil hydrogenated 20 parts, 40 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 10 parts, octadecyldiethanol amine 2 parts, disodium hydrogen phosphate 3 parts, sodium trimetaphosphate 20 parts, hydrogenated yolk lecithin 10 parts.
The preparation method promoting the compositions of absorption of insulin, comprises the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 50 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 80 DEG C, stirring reaction 20min；
(3) add octadecyldiethanol amine, stir,.
Embodiment 2
Promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 30 parts, castor oil hydrogenated 40 parts, 60 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 20 parts, octadecyldiethanol amine 8 parts, disodium hydrogen phosphate 10 parts, sodium trimetaphosphate 50 parts, hydrogenated yolk lecithin 40 parts.
The preparation method promoting the compositions of absorption of insulin, comprises the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 60 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 85 DEG C, stirring reaction 30min；
(3) add octadecyldiethanol amine, stir,.
Embodiment 3
Promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 15 parts, castor oil hydrogenated 25 parts, 55 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 18 parts, octadecyldiethanol amine 6 parts, disodium hydrogen phosphate 5 parts, sodium trimetaphosphate 35 parts, hydrogenated yolk lecithin 25 parts.
The preparation method promoting the compositions of absorption of insulin, comprises the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 58 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 80～85 DEG C, stirring reaction 26min；
(3) add octadecyldiethanol amine, stir,.
Embodiment 4
Promote the compositions of absorption of insulin, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 20 parts, castor oil hydrogenated 30 parts, 50 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 15 parts, octadecyldiethanol amine 5 parts, disodium hydrogen phosphate 6 parts, sodium trimetaphosphate 30 parts, hydrogenated yolk lecithin 30 parts.
The preparation method promoting the compositions of absorption of insulin, comprises the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 55 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 85 DEG C, stirring reaction 25min；
(3) add octadecyldiethanol amine, stir,.
Performance test
Diabetics 20, male 14 examples, female 6 example, 24～30 years old age, adopts the compositions of the present invention, measures the peak time of blood drug level, average in the 5min after using insulin.
Blank group: record the peak time of blood drug level after adopting identical insulin, result is in Table 1.
Table 1
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Blank group | |
| Peak time min | 83 | 87 | 84 | 82 | 109 |
Conclusion: the compositions of the present invention can promote the absorption of insulin, makes insulin faster play a role.
Claims (5)
1. promote the compositions of absorption of insulin, it is characterized in that, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 10～30 parts, castor oil hydrogenated 20～40 parts, 40～60 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 10～20 parts, octadecyldiethanol amine 2～8 parts, disodium hydrogen phosphate 3～10 parts, sodium trimetaphosphate 20～50 parts, hydrogenated yolk lecithin 10～40 parts.
2. the compositions of promotion absorption of insulin according to claim 1, it is characterized in that, including the raw material of following parts by weight: dimethyl dodecyl amine oxide 20 parts, castor oil hydrogenated 30 parts, 50 parts of hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride 15 parts, octadecyldiethanol amine 5 parts, disodium hydrogen phosphate 6 parts, sodium trimetaphosphate 30 parts, hydrogenated yolk lecithin 30 parts.
3. based on the preparation method of the compositions of the promotion absorption of insulin described in claim 1, it is characterised in that comprise the following steps:
(1) dimethyl dodecyl amine oxide, castor oil hydrogenated, hexadecanyl phosphate potassium, didecyl Dimethy ammonium chloride are mixed and is heated to 50 DEG C～60 DEG C；
(2) it is subsequently adding disodium hydrogen phosphate, sodium trimetaphosphate, hydrogenated yolk lecithin, is warming up to 80～85 DEG C, stirring reaction 20～30min；
(3) add octadecyldiethanol amine, stir,.
4. the preparation method of the compositions of promotion absorption of insulin according to claim 3, it is characterised in that the heating-up temperature of step (1) is 55 DEG C.
5. the preparation method of the compositions of promotion absorption of insulin according to claim 3, it is characterised in that step (2) is warming up to 85 DEG C of reaction 25min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610111649.XA CN105749292A (en) | 2016-02-29 | 2016-02-29 | Composition for promoting insulin absorption and preparation method of composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610111649.XA CN105749292A (en) | 2016-02-29 | 2016-02-29 | Composition for promoting insulin absorption and preparation method of composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105749292A true CN105749292A (en) | 2016-07-13 |
Family
ID=56330525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610111649.XA Pending CN105749292A (en) | 2016-02-29 | 2016-02-29 | Composition for promoting insulin absorption and preparation method of composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105749292A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498113A (en) * | 2001-03-23 | 2004-05-19 | ������ҽҩ�¹�����˾ | Insulin preparations, which donot contain any zinc or only small quantity of zinc of improved stability |
| CN101066058A (en) * | 2007-06-05 | 2007-11-07 | 孙保兴 | Amine oxide iodine complex disinfectant |
-
2016
- 2016-02-29 CN CN201610111649.XA patent/CN105749292A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1498113A (en) * | 2001-03-23 | 2004-05-19 | ������ҽҩ�¹�����˾ | Insulin preparations, which donot contain any zinc or only small quantity of zinc of improved stability |
| CN101066058A (en) * | 2007-06-05 | 2007-11-07 | 孙保兴 | Amine oxide iodine complex disinfectant |
Non-Patent Citations (9)
| Title |
|---|
| SHINICHIRO HIRAI ET AL: "Mechanisms for the enhancement of the nasal absorption of insulin by surfactants", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
| 吕彤: "《表面活性剂合成技术》", 31 May 2009 * |
| 吕百龄等: "《实用工业助剂全书》", 31 July 2001 * |
| 崔福德: "《药剂学 第6版》", 31 March 2011 * |
| 张殿义等: "《化妆品原料规格实用手册》", 31 March 2002 * |
| 彭安顺等: "《精细有机品化学》", 31 August 1996 * |
| 罗明生等: "《药剂辅料大全》", 31 January 2006 * |
| 邓英杰: ""增加胰岛素肠内吸收的动物试验"", 《脏器生化制药》 * |
| 黄洪周: "《中国表面活性剂总览》", 31 August 2003 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Larson et al. | Low glycemic index treatment for epilepsy in tuberous sclerosis complex | |
| Saleh et al. | Management of erectile dysfunction post-radical prostatectomy | |
| CN108079281A (en) | For the pharmaceutical composition of the glycemic control in diabetes B patient | |
| Willey et al. | The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes | |
| Cruz et al. | Conjunctival tattoo: report on an emerging body modification trend | |
| CN105749292A (en) | Composition for promoting insulin absorption and preparation method of composition | |
| DE69231036T2 (en) | METHOD FOR TREATING PATIENTS WITH CHRONIC LIVER DISEASE | |
| BR9915962A (en) | Pyridinium Series Compound, processes for the preparation of Pyridinium Series Compound and a parenteral formulation, use of a compound, pharmaceutical composition to treat diabetic complications and aging-related diseases, and, method for treating a diabetic patient and preventing or treat diseases caused by complications associated with diabetes and aging | |
| Cheema et al. | Berardinelli-Seip congenital generalised lipodystrophy | |
| Chen et al. | HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study | |
| KR20130041494A (en) | The composition for treating diabetes | |
| Yanovitch et al. | Travoprost in children: adverse effects and intraocular pressure response | |
| CA2520757A1 (en) | Method and composition for treatment of diabetes mellitus and impaired glucose tolerance | |
| EP0913153B1 (en) | Use of thiamines for the manufacture of a medicament to prevent and treat diabetic retinopathy and diabetic nephropathy | |
| CN113171423A (en) | Health-preserving health-care tea for tonifying qi and blood as well as preparation method and application thereof | |
| KR20020071326A (en) | Composition for improving erectile dysfunction and foods containing the same | |
| CN106466325B (en) | A kind of medicine, composition and preparation for preventing or treating diabetes | |
| Bradley | Intensive insulin therapy in critically ill patients | |
| CN100409762C (en) | Konjaku flour suitable for diabetes | |
| Fishman | A historical perspective on the early treatment of night blindness and the use of dubious and unproven treatment strategies for patients with retinitis pigmentosa | |
| RU2457834C1 (en) | Method of treating metabolic syndrome | |
| John | Further observations on the treatment of hyperinsulinism with insulin | |
| WO2024090549A1 (en) | Agent for preventing or ameliorating neuropathy | |
| McGregor | Thiouracil and its effects upon hyperthyroidism | |
| CN106511544A (en) | Composition for reducing blood glucose and application of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160713 |